5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy

Bibliography

• Harrop R, Ryan M. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated. Cancer Immunol Immunother 2006;55(9):1081-90
   PubMed Web of Science ®Google Scholar
• Harrop R, Connolly NB, Redchenko I, Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 2006;12(11):3416-24
   PubMed Web of Science ®Google Scholar
• Harrop R, Drury N, Shingler W, Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 2007;13(15 Pt 1):4487-94
   PubMed Web of Science ®Google Scholar
• Harrop R, Hawkins RE, Anthoney A, An open label phase II study of modified vaccinia ankara (MVA) expressing the tumor antigen 5T4 given in conjunction with chemotherapy: safety and immunogenicity before, during and after chemotherapy. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23(16S):2578
   Google Scholar
• Dangoor A, Burt D, Harrop R, A vaccinia-based vaccine (TroVax) targeting the oncofetal antigen 5T4 administered before and after surgical resection of colorectal cancer liver metastases: phase II trial. 2006 ASCO Annual Meeting Proceedings. J Clin Oncol 2006;24(18S):2574
   Google Scholar
• Kaufman HL, Deraffele G, Mitcham J, A phase I clinical trial of MVA expressing 5T4 and high-dose interleukin-2 (IL-2) for metastatic renal cell carcinoma. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18S):12500
   Google Scholar
• Amato R, Shingler W, Naylor S, Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial. Clin Cancer Res 2008;14(22):7504-10
   PubMed Web of Science ®Google Scholar
• Amato R, Shingler W, Goonewardena M, Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. J Immunother 2009;32(7):765-72
   PubMed Web of Science ®Google Scholar
• Hawkins R, Harrop R, Naylor S, TRIST: a randomised, double blind, placebo controlled phase III study of MVA-5T4 in metastatic renal cancer patients. Eur J Cancer Suppl 2009;7(3):11
   Google Scholar
• Amato R, Drury N, Naylor S, Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother 2008;31(6):577-85
   PubMed Web of Science ®Google Scholar
• Hole N, Stern PL. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer 1988;57:237-46
   Web of Science ®Google Scholar
• Southall P, Boxer G, Bagshaw K, Immunological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer 1990;61:89-95
   PubMed Web of Science ®Google Scholar
• Starzynska T, Marsh P, Schofield P, Prognostic significance of 5T4 oncofoetal antigen expression in colorectal carcinoma. Br J Cancer 1994;69:899-902
   PubMed Web of Science ®Google Scholar
• Griffiths RW, Gilham DE, Dangoor A, Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer 2005;93(6):670-7
   PubMed Web of Science ®Google Scholar
• Barrow KM, Ward CM, Rutter J, Embryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epithelia. Dev Dyn 2005;233(4):1535-45
   PubMed Web of Science ®Google Scholar
• Carsberg C, Myers KA, Stern PL. Metastasis-associated 5T4 antigen disrupts cell–cell contacts and induces cellular motility in ephithelial cells. Int J Cancer 1996;68(1):84-92
   PubMed Web of Science ®Google Scholar
• Carroll MW, Restifo NP. Poxviruses as vectors for cancer immunotherapy. In: Stern PL, Beverley PCL, Carroll MW, editors, Cancer vaccines and immunotherapy. Cambridge University Press, Cambridge, UK; 2000. p. 47-65
   Google Scholar
• Sutter G, Moss B. Non-replicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992;89:10847-51
   PubMed Web of Science ®Google Scholar
• Rochlitz C, Figlin R, Squiban P, Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 2003;5(8):690-9
   PubMed Web of Science ®Google Scholar
• Eder J, Kantoff P, Roper K, A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000;6(5):1632-8
   PubMed Web of Science ®Google Scholar
• Marshall J, Hoyer R, Toomey M, Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000;18(23):3964-73
   PubMed Web of Science ®Google Scholar
• Marlow S. Trovax Gene Therapy Vaccine Product: Investigator's Brochure Oxford, Oxford Biomedica, 2006
   Google Scholar
• Redchenko I, Harrop R, Ryan MG, Identification of a major histocompatibility complex class I-restricted epitope in the tumour-associated antigen, 5T4. Immunology 2006;118:50-7
   PubMed Web of Science ®Google Scholar
• Motzer R, Mazumdar M, Bacik J, Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-40
   PubMed Web of Science ®Google Scholar
• Yang J, Sherry R, Steinberg S, Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127-32
   PubMed Web of Science ®Google Scholar
• Tannock I, De Wit R, Berry W, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12
   PubMed Web of Science ®Google Scholar
• Petrylak D, Tangen C, Hussain M, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20
   PubMed Web of Science ®Google Scholar
• Rini B, Bok R, Small E. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol 2003;21(1):99-105
   PubMed Web of Science ®Google Scholar
• Small E, Reese D, Um B, Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999;5:1738-44
   PubMed Web of Science ®Google Scholar